Cigna's shares have surged 4.9% year-to-date, bolstered by a strong 'Strong Buy' consensus from analysts, as the company reports a 10.4% year-over-year revenue increase to $72.5 billion for Q4 fiscal 2025. This financial performance coincides with the resolution of Federal Trade Commission matters, including a $7 billion settlement related to pharmacy benefits, and the launch of a new rebate-free pharmacy benefit model. Cigna is projected to achieve approximately $280 billion in consolidated adjusted revenue by 2026, reflecting its robust market position despite ongoing scrutiny over fee arrangements.
“Companies with ex-dividend date · include · Allstate, Lam Research, Cigna, Qualcomm · next week”
“The Cigna Group · is based in · Bloomfield, Connecticut · true”
“The Cigna Group · has a market cap of · nearly $76 billion · true”
“CI stock · has gained · 4.9% year-to-date · true”
“Cigna expects full-year 2026 consolidated adjusted revenue · to be approximately · $280 billion · true”
“CI stock · carries a · 'Strong Buy' consensus rating from 23 analysts · true”
“Cigna · is accused of · allegedly improper fee arrangements · related to rebate diversion”
“Cigna · has a Federal Trade Commission settlement · tied to pharmacy benefits operations · US$7 billion customer out-of-pocket relief over ten years”
“Cigna Group · projects · $299.7 billion revenue · by 2028”
“Cigna Group · projects · $7.8 billion earnings · by 2028”
“The Cigna Group · is based in · Bloomfield, Connecticut · true”
“The Cigna Group · is a · diversified health services leader · true”
